BioCentury
ARTICLE | Clinical News

Alexion completes Phase II 5G1.1 enrollment

August 24, 2000 7:00 AM UTC

ALXN completed enrollment of 200 rheumatoid arthritis patients in its double-blind, placebo-controlled U.S. Phase II trial of 5G1.1. The trial is designed to assess safety and clinical efficacy of rep...